A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Gilead Sciences
Incyte Corporation
NextCure, Inc.
Acerta Pharma BV
St. Jude Children's Research Hospital
Therapeutic Advances in Childhood Leukemia Consortium
Amgen
City of Hope Medical Center
Merck Sharp & Dohme LLC
Thomas Jefferson University
Big Ten Cancer Research Consortium
BeiGene
Children's Oncology Group
Pfizer
Therapeutic Advances in Childhood Leukemia Consortium
Stanford University
AstraZeneca
BeiGene
University of California, San Diego
Menarini Group
M.D. Anderson Cancer Center
Altor BioScience
Amgen
M.D. Anderson Cancer Center
Amgen
Amgen
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
Arog Pharmaceuticals, Inc.
Gilead Sciences
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
AbbVie
Bristol-Myers Squibb
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Atara Biotherapeutics
Amgen
Precision BioSciences, Inc.
AbbVie
Molecular Templates, Inc.
BeiGene
Washington University School of Medicine
Daiichi Sankyo
Therapeutic Advances in Childhood Leukemia Consortium
ERYtech Pharma
University of Michigan Rogel Cancer Center